Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/8/2020
SIETES contiene 93082 citas

 
 
 1 a 20 de 1762 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in covid-19. N Engl J Med 2020;382:18 de junio. [Ref.ID 103602]
2. Cita con resumen
Zhang PZhi L, Cai J, Lei F, Qin J-J, Xie J, Liu Y-M, Zhao Y-C, Huang X, Lin L, Xia M, Chen M-M, Cheng X, Zhang X, Guo D, Peng Y, Ji Y-X, Chen J, She Z-G, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, et al.. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circulation Research 2020:17 de abril. [Ref.ID 103594]
5. Cita con resumen
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respiratory Medicine 2020:11 de marzo. [Ref.ID 103569]
6. Cita con resumen
Herman AO. FDA approves new cholesterol-lowering drug. Journal Watch 2020:24 de febrero. [Ref.ID 103538]
7. Cita con resumen
Hripcsak G, Suchard MA, Shea S, Chen RJ, You SC, Pratt N, Madigan D, Krumholz HM, Ryan PB, Schuemie MJ. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020:17 de febrero. [Ref.ID 103537]
8.Enlace a cita original Cita con resumen
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ 2020;368:5 de febrero. [Ref.ID 103514]
9. Cita con resumen
McEvoy JB, Daya N, Rahman F, Hoogeveen RC, Blumenthal RS, Shah AM, Ballantyne CM, Coresh J, Selvin E. Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood pressure guideline with incident cardiovascular outcomes. JAMA 2020;323:28 de enero. [Ref.ID 103512]
10. Cita con resumen
Pasternak B, Ueda P, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveern K, Jonasson C, Wintzell V, Melbye M, Svanström H. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ 2019;366:29 de agosto. [Ref.ID 103243]
11.Enlace a cita original Cita con resumen
Simó Miñana J. Guerras médicas: a propósito del ensayo EXCEL . Salud, dinero y atención primaria 2019:15 de diciembre. [Ref.ID 103225]
12. Cita con resumen
Azzouz B, Morel A, Kanagaratman L, Herlem E, Trenque T. Psoriasis after exposure to angiotensin-converting enzyme inhibitors: French pharmacovigilance data and review of the literature. Drug Saf 2019;42:diciembre. [Ref.ID 103209]
13.Enlace a cita original Cita con resumen
Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen RJ, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:24 de octubre. [Ref.ID 103199]
14.Enlace a cita original Cita con resumen
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereschchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M, for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:21 de noviembre. [Ref.ID 103194]
15.Enlace a cita original Cita con resumen
Korol S, White M, O'Meara E, Rouleau JL, White-Guay B, Dorais M, Ahmed A, de Denus S, Perreault S. Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?. Eur J Clin Pharmacol 2019;75:837-47. [Ref.ID 103176]
16. Cita con resumen
Thayakaran R, Adderley NJ, Sainsbury C, Torlinska B, Sumilo D, Thomas GN, Toulis KA, Nirantharakumar K. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. BMJ 2019;366:3 de septiembre. [Ref.ID 103172]
18.Enlace a cita original Cita con resumen
Modin D, Jorgensen ME, Gislason S, Jensen JS, Kober L, Claggett B, Hegde SM, Solomon SD, Torp-Pedersen C, Biering-Sorensen T. Influenza vaccine in heart failure cumulative number of vaccinations, frequency, timing, and survival: a Danish nationwide cohort study. Circulation 2018;139:10 de diciembre. [Ref.ID 102908]
19.Enlace a cita originalTiene citas relacionadas Cita con resumen
Yancy CW. Sodium restriction in heart failure: too much uncertainty — Do the trials. JAMA Intern Med 2018:5 de noviembre. [Ref.ID 102849]
20.Enlace a cita originalTiene citas relacionadas Cita con resumen
The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102844]
Seleccionar todas
 
 1 a 20 de 1762 siguiente >>